Independent non-profit professional association advancing heart and vascular health
A wave of studies finds that AI analysis of mammograms can identify cardiovascular risks in women, including hypertension, coronary heart disease and stroke, alongside breast cancer screening. Researchers say mammograms could become a dual-purpose tool for early cardiovascular risk detection, prompting earlier intervention.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
A Berlin-led study presented at the ESC Congress finds higher blood levels of xylitol are associated with increased risk of major cardiovascular events. The association is dose-dependent and persists across age and risk factors, prompting calls for further research.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
A seven-year study of about 41,000 adults in South Korea finds that modest weekend catch-up sleep—about 1 hour 27 minutes—reduces the risk of high blood pressure by up to 9%, with larger benefits for physically inactive individuals. Excessive weekend sleep (>4 hours) may offset gains. Findings were presented at the European Society of Cardiology congress in Munich.
England expands a seven-minute cholesterol test to 100 pharmacies as part of a national push to spot heart-disease risk early. Patients aged 40-84 without recent tests can get a fingertip cholesterol reading, a blood pressure check, and tailored lifestyle advice. Early detection aims to reduce heart attacks, strokes, and NHS pressure.
A synthesis of recent sleep studies shows wearables may misjudge sleep quality, narcolepsy treatment advances gain regulatory traction, and weekend catch-up sleep ties to lower hypertension risk, prompting a nuanced view of how to monitor and improve sleep.